Comparative evaluation of hormonal-metabolic status of endometrial cancer patient´s over the past five decades

Abstract

Comparative analysis of changes in hormonal-metabolic status of patients with endometrial cancer seen in the Research Institute of Oncology named after N.N. Petrov for over 50 years is presented. Over the past half century there was a gradual evolution of some indicators characterizing patients with endometrial cancer: increased age at the time of diagnosis from 57,43 ± 0,91 years in 1965-1967 to 60,66 ± 0,73 years 2012-2015 and changes in the anthropometric characteristics (in addition to increasing growth, increased body weight, circumference of waist and hip, the proportion of women with high body mass index). Also, increased manifestations of disorders of lipid and carbohydrate metabolism, including triglyceride levels, blood glucose and insulinemia were revealed. Reflecting the dynamics of processes occurring with the female population in general, the revealed changes, at the same time, represent an important component of conditions conducive to the increase in the incidence of endometrial cancer.

Keywords

endometrial cancer / hormonal and metabolic status / a comparative dynamic evaluation

References

[1] Белоцерковцева Л.Д., Коваленко Л.В., Корнеева Е.В., и др. Критерии диагностики метаболического синдрома // Особенности метаболического синдрома у женщин в различные периоды жизни: патогенез, клиника, диагностика, лечение. - М., 2010. - С. 36-38. [Belocerkovceva LD, Kovalenko LV, Korneeva EV, et al. Criteria for diagnosis of metabolic syndrome. In: Osobennosti metabolicheskogo sindroma u zhenshhin v razlichnye periody zhizni: patogenez, klinika, diagnostika, lechenie. Moscow; 2010. P. 36-38. (In Russ).]

[2] Берштейн Л.М. Выделение классических эстрогенов и суммарных фенолстероидов у больных раком тела матки: Дис. … канд. мед. наук. - Л., 1967. [Bershtejn LM. Vydelenie klassicheskih jestrogenov i summarnyh fenolsteroidov u bol’nyh rakom tela matki [dissertation]. Leningrad; 1967. (In Russ).]

[3] Берштейн Л.М., Берлев И.В., Васильев Д.А., и др. Ожирение и особенности рака эндометрия: меняется ли что-нибудь с годами? // Вопросы онкологии. 2015. - Т. 61. - № 4. - С. 575-579. [Bershtejn LM, Berlev IV, Vasil’ev DA, et al. Ozhirenie i osobennosti rak jendometrija: menjaetsja li chto-nibud’ s godami? Voprosy onkologii. 2015; 61(4):575-79. (In Russ).]

[4] Бохман Я.В. Рак тела матки. - Кишенев: Штиинца, 1972. [Bohman JV. Rak tela matki. Kishenev: Shtiinca; 1972. (In Russ).]

[5] Данова Л.А. О некоторых функциях печени и особенностях углеводного обмена у больных раком тела матки: Дис. … канд. мед. наук. - Л., 1968. [Danova LA. O nekotoryh fukcijah pecheni i osobennostjah uglevodnogo obmena u bol’nyh rakom tela matki [dissertation]. Leningrad; 1968. (In Russ).]

[6] Состояние онкологической помощи населению России в 2014 году / Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. - М., 2015. [Sostojanie onkologicheskoj pomoshhi naseleniju Rossii v 2014 godu. Pod red. A.D. Kaprina, V.V. Starinskogo, G.V. Petrovoj. M.; 2015. (In Russ).]

[7] Коваленко И.М., Берштейн Л.М. Сахарный диабет как модификатор течения опухолей женской репродуктивной сферы // Вопросы онкологии. - 2014. - Т. 60. - № 1. - С. 25-31. [Kovalenko IM, Bershtejn LM. Saharnyj diabet kak modifikator techenija opuholej zhenskoj reproduktivnoj sfery. Voprosy onkologii. 2014;60(1):25-31. (In Russ).]

[8] Миронов Б.Н. Историческая антропометрия: задачи, теория и методология // Благосостояние населения и революции в имперской России: XVIII - начало ХХ века. - М., 2010. - С. 75-98. [Mironov BN. Istoricheskaja antropometrija: zadachi, teorija i metodologija. Historical anthropometrics: goals, theory and methodology. Blagosostojanie naselenija i revoljucii v imperskoj Rossii: XVIII - nachalo HH veka. Moscow; 2010:75-98. (In Russ).]

[9] Руднев С.Г., Соболева Н.П., Стерликов С.А., и др. Биоимпедансное исследование состава тела населения России. - М.: РИО ЦНИИОИЗ, 2014. [Rudnev SG, Soboleva NP, Sterlikov SA, et al. Bioimpedansnoe issledovanie sostava tela naselenija Rossii. M.: RIO CNIIOIZ; 2014. (In Russ).]

[10] Чернышова А.Л., Коломиец Л.А., Юнусова Н.В., Кондакова И.В. Прогноз течения рака эндометрия у больных с метаболическим синдром // Онкогинекология. - 2012. - № 2. - С. 32-38. [Chernyshova AL, Kolomiec LA, Junusova NV, Kondakova IV. Prognoz techenija raka jendometrija u bol’nyh s metabolicheskim sindrom. Onkoginekologija. 2012;2:32-8. (In Russ).]

[11] Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the Metabolic Syndrome. A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640-5. doi: 10.1161/CIRCULATIONAHA.109.192644.

[12] Ali AT. Reproductive factors and the risk of endometrial cancer. J Gynecol Cancer. 2014;24 (3):384-93. doi: 10.1097/IGC.0000000000000075

[13] Arem H, Irwin ML. Obesity and endometrial cancer survival: a systematic review. J Obes. 2013;37(5):634-9. doi: 10.1038/ijo.2012.94

[14] Bartosch C, Gomes B, Jerónimo C, Lopes JM. Endometrial carcinoma in Portugal: demographic, diagnostic and treatment changes in the last 5 decades. Int J Gynecol pathol. 2015;34(2):159-68. doi: 10.1097/PGP.0000000000000124

[15] Branca F, Nikogosian H, Lobstein T. Проблема ожирения в Европейском регионе ВОЗ и стратегии ее решения. Копенгаген: Европейское региональное бюро ВОЗ; 2009. [Branca F, Nikogosian H, Lobstein T. Problema ozhireniya v Evropejskom regione VOZ i strategii ee resheniya. Kopengagen: Evropejskoe regional’noe byuro VOZ; 2009.]

[16] Bromley C, et al. The Scottish health survey. 2003; 2. Adults. Edinburgh: Scottish Executive Health Department; 2005.

[17] Carlson MJ, Theil K, Yang S, Leslie KK. Catch it before it kills: progesterone, obesity, and the prevention of endometrial cancer. Discov Med. 2012;14(76):215-22.

[18] Evans T, Sany O, Pearmain P, Ganesan R, Blann A, Sundar S. Differential trends in the rising incidence of endometrial cancer by type: data from a UK population-based registry from 1994 to 2006. Br J Cancer. 2011;104(9):1505-10. doi: 10.1038/bjc.2011.68

[19] Esposito K, Chiodini P, Capuano A, et al. Metabolic syndrome and endometrial cancer: a meta-analysis. Endocrine. 2014;45(1):28-36. doi: 10.1007/s12020-013-9973-3

[20] Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2005;48:1684-99. doi: 10.1007/s00125-005-1876-2

[21] Liao C, Zhang D, Mungo C, et al. Is diabetes mellitus associated with increased incidence and disease-specific mortality in endometrial cancer? A systematic review and meta-analysis of cohort studies. Gynecol Oncol. 2014;135(1):163-71. doi: 10.1016/j.ygyno.2014.07.095

[22] Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-9. doi: 10.1007/BF00280883

[23] McAuley KA, Williams SM, Mann JI, et al. Diagnosing insulin resistance in the general population. Diabetes Care. 2001;24:460-4. doi: 10.2337/diacare.24.3.460

[24] Seidell JC. Waist circumference and waist/hip ratio in relation to all cause mortality, cancer and sleep apnea. Eur J Clin Nutrition. 2010;64(1):35-41. doi: 10.1038/ejcn.2009.71

[25] Waist circumference and waist-hip ratio: report of a WHO expert consultation. Geneva, 8-11 December 2008. Geneva: WHO; 2011.

[26] Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487-95. doi: 10.2337/diacare.27.6.1487

[27] WHO. Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO consultation. Geneva: WHO; 1999.

RIGHTS & PERMISSIONS

Baltrukova A.N., Berlev I.V., Berstein L.M.